|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
SE8804164A0
(sv)
|
1988-11-17 |
1990-05-18 |
Per Prisell |
Farmaceutisk beredning
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
US5177197A
(en)
|
1990-02-27 |
1993-01-05 |
Ludwig Institute For Cancer Research |
Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
|
|
US5229495A
(en)
|
1991-06-18 |
1993-07-20 |
Ludwig Institute For Cancer Research |
Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
WO1994005800A1
(en)
|
1992-09-03 |
1994-03-17 |
The Regents Of The University Of California |
Dorsal tissue affecting factor and compositions
|
|
US5453492A
(en)
|
1993-07-28 |
1995-09-26 |
La Jolla Cancer Research Foundation |
60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
|
|
CA2189340A1
(en)
|
1994-05-04 |
1995-11-16 |
James W. Dennis |
Modulators of cytokines of the tgf-.beta. superfamily and methods for assaying for same
|
|
US5616561A
(en)
|
1995-03-31 |
1997-04-01 |
Regents Of The University Of California |
TGF-β antagonists as mitigators of radiation-induced tissue damage
|
|
US6610510B1
(en)
|
1997-04-29 |
2003-08-26 |
Regeneron Pharmaceuticals, Inc. |
Morphogenic proteins
|
|
IL133316A0
(en)
|
1997-06-06 |
2001-04-30 |
Regeneron Pharma |
Ntn-2 member of tnf ligand family
|
|
US5935852A
(en)
|
1997-07-03 |
1999-08-10 |
Genetics Institute, Inc. |
DNA molecules encoding mammalian cerberus-like proteins
|
|
WO1999061044A1
(en)
|
1998-05-28 |
1999-12-02 |
The Board Of Trustees Of The University Of Arkansas |
Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
|
|
WO2000022909A2
(en)
|
1998-10-19 |
2000-04-27 |
Biotech Australia Pty. Limited |
Systems for oral delivery
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
EP1721979B1
(en)
|
1998-11-27 |
2010-09-15 |
Ucb, S.A. |
Compositions and methods for increasing bone mineralisation
|
|
AU3511100A
(en)
|
1999-03-12 |
2000-10-04 |
Regeneron Pharmaceuticals, Inc. |
Novel nucleic acids and polypeptides
|
|
US7358056B1
(en)
|
1999-08-30 |
2008-04-15 |
Signal Pharmaceuticals |
Methods for modulating signal transduction mediated by TGF-β and related proteins
|
|
CA2395926A1
(en)
|
1999-12-28 |
2001-07-05 |
Curagen Corporation |
Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
|
|
AU2001236519A1
(en)
|
2000-01-24 |
2001-07-31 |
Millennium Pharmaceuitcals, Inc. |
Identification, assessment, prevention, and therapy of prostate cancer
|
|
AU2001229508A1
(en)
|
2000-01-31 |
2001-08-07 |
Human Genome Sciences, Inc. |
Nucleic acids, proteins, and antibodies
|
|
EP1290217A2
(en)
|
2000-02-04 |
2003-03-12 |
Aeomica, Inc. |
Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
|
|
IL152785A0
(en)
|
2000-05-12 |
2003-06-24 |
Univ Utah Res Found |
Compositions and methods for cell dedifferentiation and tissue regeneration
|
|
US20040087016A1
(en)
|
2000-05-12 |
2004-05-06 |
University Of Utah Research Foundation |
Compositions and methods for cell dedifferentiation and tissue regeneration
|
|
JP2003534813A
(ja)
|
2000-06-01 |
2003-11-25 |
アムジェン インコーポレーテッド |
シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用
|
|
WO2001098491A2
(en)
|
2000-06-19 |
2001-12-27 |
F. Hoffmann-La Roche Ag |
Osteolevin gene polymorphisms
|
|
AU2002236558A1
(en)
|
2000-12-01 |
2002-06-11 |
Regents Of The University Of California |
Method and composition for modulating bone growth
|
|
US20020159986A1
(en)
|
2001-01-12 |
2002-10-31 |
John Langenfeld |
Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
|
|
US20040235728A1
(en)
|
2001-11-08 |
2004-11-25 |
Stoch Selwyn Aubrey |
Compositions and methods for treating osteoporosis
|
|
EP1504099A4
(en)
|
2001-12-10 |
2006-05-10 |
Nuvelo Inc |
NEW NUCLEIC ACIDS AND POLYPEPTIDES
|
|
GB0130738D0
(en)
|
2001-12-21 |
2002-02-06 |
Serono Internat S A |
Protein
|
|
GB2385052A
(en)
|
2002-02-05 |
2003-08-13 |
Leuven K U Res & Dev |
Treatment of spondyloarthropathies
|
|
US20030186915A1
(en)
|
2002-02-11 |
2003-10-02 |
Yang Pan |
Regulatory polynucleotides and uses thereof
|
|
JP2005253301A
(ja)
|
2002-02-20 |
2005-09-22 |
Taisho Pharmaceut Co Ltd |
骨形成蛋白結合領域を有する蛋白質及びそれをコードする遺伝子
|
|
CA2476410C
(en)
|
2002-03-01 |
2013-09-24 |
Celltech R & D, Inc. |
Methods to increase or decrease bone density
|
|
WO2003087763A2
(en)
|
2002-04-03 |
2003-10-23 |
Celltech R & D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
|
AU2003228958C1
(en)
|
2002-05-17 |
2009-01-08 |
Fidia Advanced Biopolymers, S.R.L. |
Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
|
|
AU2003276430A1
(en)
|
2002-06-14 |
2003-12-31 |
Stowers Institute For Medical Research |
Wise/sost nucleic acid sequences and amino acid sequences
|
|
JP2006513159A
(ja)
|
2002-11-01 |
2006-04-20 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーターとしてのカルボニルアミノ−ベンズイミダゾール誘導体
|
|
WO2004062621A2
(en)
|
2003-01-13 |
2004-07-29 |
Georgia Tech Research Corporation |
Anti-inflammatory agents and methods of their use
|
|
PL1608399T3
(pl)
|
2003-03-14 |
2012-09-28 |
Ucb Mfg Inc |
Kompleks sklerostyny i nogginy lub chordyny, oraz czynniki modulujące tworzenie tego kompleksu
|
|
US7351698B2
(en)
|
2003-05-07 |
2008-04-01 |
Merck & Co., Inc. |
Androgen receptor modulators and methods of use thereof
|
|
NO345763B1
(no)
|
2003-06-16 |
2021-07-19 |
Celltech R&D Inc |
Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering.
|
|
AU2004269920A1
(en)
|
2003-09-11 |
2005-03-17 |
Association Francaise Retinitis Pigmentosa (Afrp) |
Novel targets for the treatment of retina diseases
|
|
US8461155B2
(en)
|
2003-09-22 |
2013-06-11 |
University Of Connecticut |
Sclerostin and the inhibition of WNT signaling and bone formation
|
|
EP1670425A4
(en)
|
2003-10-07 |
2008-04-16 |
Quark Pharmaceuticals Inc |
BONE MORPHOGENETIC PROTEIN (BMP) 2A AND ITS APPLICATIONS
|
|
EP1758613A2
(en)
|
2004-05-14 |
2007-03-07 |
Baylor College Of Medicine |
Compositions and methods for modulating bone mass
|
|
WO2005118636A2
(en)
|
2004-05-27 |
2005-12-15 |
Acceleron Pharma Inc. |
Tgf derepressors and uses related thereto
|
|
EP1863340A2
(en)
|
2005-03-11 |
2007-12-12 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
US7592429B2
(en)
*
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
|
US20060293667A1
(en)
|
2005-05-19 |
2006-12-28 |
Agnes Vignery |
Bone implant device and methods of using same
|
|
WO2006135734A2
(en)
|
2005-06-10 |
2006-12-21 |
The Regents Of The University Of California |
Compositions and methods for altering bone density and bone patterning
|
|
US8541177B2
(en)
|
2006-01-13 |
2013-09-24 |
A Chan Holding B.V. |
Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
|
|
EP2423226A3
(en)
|
2006-11-10 |
2012-05-30 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
|
WO2008133722A2
(en)
|
2006-11-10 |
2008-11-06 |
Ucb Pharma S.A. |
Anti human sclerostin antibodies
|
|
PL3345607T3
(pl)
|
2006-12-29 |
2023-01-09 |
Ossifi-Mab Llc |
Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
|
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
MX2010006519A
(es)
|
2007-12-14 |
2010-10-15 |
Amgen Inc |
Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
|
|
AR075715A1
(es)
*
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
|
WO2010115932A1
(en)
*
|
2009-04-08 |
2010-10-14 |
Novartis Ag |
Combination for the treatment of bone loss
|
|
SMT202000095T1
(it)
|
2010-05-14 |
2020-03-13 |
Amgen Inc |
Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
|
|
US9617323B2
(en)
|
2010-06-07 |
2017-04-11 |
Joshua Rabbani |
Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor
|
|
EP2632951B1
(en)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Dkk1 antibodies and methods of use
|
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
|
SG193610A1
(en)
|
2011-03-25 |
2013-11-29 |
Amgen Inc |
Anti - sclerostin antibody crystals and formulations thereof
|
|
ES2823240T3
(es)
|
2011-04-19 |
2021-05-06 |
Amgen Inc |
Método para el tratamiento de la osteoporosis
|
|
PT2739311T
(pt)
|
2011-08-04 |
2018-03-26 |
Amgen Inc |
Método para tratamento de defeitos de lacunas ósseas
|
|
CN104039828B
(zh)
|
2011-12-28 |
2017-07-21 |
安进公司 |
通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法
|
|
EP3626267A1
(en)
|
2012-07-05 |
2020-03-25 |
UCB Pharma, S.A. |
Treatment for bone diseases
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
|
SG10202101105XA
(en)
|
2015-08-13 |
2021-03-30 |
Amgen Inc |
Charged depth filtration of antigen-binding proteins
|
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
|
MA45921A
(fr)
|
2016-08-08 |
2019-06-19 |
Amgen Inc |
Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
|
|
JP2020502218A
(ja)
*
|
2016-12-21 |
2020-01-23 |
メレオ バイオファーマ ３ リミテッド |
骨形成不全症の処置における抗スクレロスチン抗体の使用
|
|
IL267430B1
(en)
|
2016-12-21 |
2025-09-01 |
Mereo Biopharma 3 Ltd |
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
|
|
AU2018235928B2
(en)
|
2017-03-14 |
2023-09-21 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
UA127219C2
(uk)
|
2017-07-27 |
2023-06-14 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
Фармацевтична композиція, що містить анти-sost антитіло, та її застосування
|
|
AU2019243848B2
(en)
|
2018-03-26 |
2025-01-02 |
Amgen Inc. |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
IL316596A
(en)
|
2018-03-30 |
2024-12-01 |
Amgen Inc |
C-terminal antibody variants
|
|
IL280642B2
(en)
|
2018-08-10 |
2025-09-01 |
Amgen Inc |
Method for preparing a pharmaceutical formulation for an antibody
|